Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07309445 · ClinicalTrials.gov registry record

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

A clinical trial of Non-Muscle Invasive Bladder Neoplasms, sponsored by Janssen Research & Development.

Recruiting
Registry status
150
Enrollment target
1
Study location

NCT07309445: Recruiting study of Non-Muscle Invasive Bladder Neoplasms, sponsored by Janssen Research & Development.

NCT07309445 is a study of Non-Muscle Invasive Bladder Neoplasms that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 150 participants, below the 289-participant average among 6 other Non-Muscle Invasive Bladder Neoplasms trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07309445, a study of Non-Muscle Invasive Bladder Neoplasms, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in participants with non-muscle invasive bladder cancer (NMIBC; an early-stage bladder cancer that is limited to the inner lining of bladder).

Primary Outcome

DFS is defined as the time from first TAR-200 initiation date to the time of the first recurrence of NMIBC (Ta, any T1 or carcinoma in-situ \[CIS)\], progression (to muscle invasive bladder cancer \[MIBC; T greater than or equal to {\>=} 2\] or to lymph node \[N+\] or to distant disease \[M+\], whichever occurs first), or death due NMIBC, whichever occurs first.

Conditions Studied

Non-Muscle Invasive Bladder Neoplasms

Study Locations (1)

Arkansas

  • Arkansas Urology - Little Rock

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2026-04-01
Est. Completion 2029-03-31
Janssen Research & Development

593 total trials

What NCT07309445 shows while recruiting

NCT07309445 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 289-participant average among 6 other Non-Muscle Invasive Bladder Neoplasms trials with a reported enrollment target (48% lower).

The record links to 1 condition, with Non-Muscle Invasive Bladder Neoplasms appearing as the primary indexed condition, and to 0 interventions.

NCT07309445 reports a single indexed study location in Arkansas.

Frequently Asked Questions

What is clinical trial NCT07309445 about?

NCT07309445 is a clinical study titled "A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States". The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in participants with non-muscle invasive bladder cancer (NMIBC;...

What is the current status of trial NCT07309445?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2026-04-01. Estimated completion is 2029-03-31.

What conditions does trial NCT07309445 study?

This clinical trial studies the following conditions: Non-Muscle Invasive Bladder Neoplasms.

Who is sponsoring clinical trial NCT07309445?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07309445 being conducted?

This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Muscle Invasive Bladder Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07309445

Source: ClinicalTrials.gov NCT07309445, the US trial registry maintained by the National Library of Medicine. NCT07309445 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.